<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119162">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01670370</url>
  </required_header>
  <id_info>
    <org_study_id>JSPH-001</org_study_id>
    <nct_id>NCT01670370</nct_id>
  </id_info>
  <brief_title>Trial of GemOx±R Regimen in First-line Treatment of Elderly Aggressive B Cell Lymphoma</brief_title>
  <official_title>Randomized Controlled Trial of GemOx±R Regimen in First-line Treatment of Elderly Aggressive B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WEI XU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Province Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate efficacy and safety of GemOx(Gemcitabine and
      Oxaliplatin) combination with rituximab(R) as first-line treatment of elderly patients with
      aggressive B cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemcitabine and Oxaliplatin(GemOx) shows effective activity in patients with relapsed
      diffuse large-cell lymphoma and other solid tumors. Until now there is no clinical trial to
      evaluate its role in patients with elderly aggressive B cell lymphoma. The investigators
      therefore developed a two-weekly regimen of rituximab combined with GemOx regimen to treat
      elderly aggressive B cell lymphoma and investigate its safety and efficacy.

      Primary Outcome Measures:

        -  overall response rate

      Secondary Outcome Measures:

        -  progression free survival

        -  overall survival

        -  safety and toxicity

      Enrollment:  100 Study Start Date: January 2012 Primary Completion Date: Dec 2012
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>overall response rate after treated by R±GemOx regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>the length of time during and after treatment during which the disease being treated does not get worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>the time frame of enrolled patients from diagnosed to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 30 days following the last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All the treatment related adverse events was evaluated according to common terminology criteria adverse events(CTCAE) version 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aggressive B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab+Gemcitabine+oxaliplatin (R-GemOx)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab: 375 mg/m2 IV day0, Gemcitabine 1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1(every 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine+oxaliplatin (GemOx)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1(every 14 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-GemOx</intervention_name>
    <description>Rituximab Gemcitabine Oxaliplatin</description>
    <arm_group_label>Rituximab+Gemcitabine+oxaliplatin (R-GemOx)</arm_group_label>
    <other_name>Rituximab</other_name>
    <other_name>Gemcitabine</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GemOx</intervention_name>
    <description>Gemcitabine oxaliplatin</description>
    <arm_group_label>Gemcitabine+oxaliplatin (GemOx)</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed aggressive B cell lymphoma;

          2. New-diagnosed and untreated;

          3. Age older than 70 years or older than 60 years with ECOG PS ≥ 2;

          4. Understand and voluntarily sign an informed consent form, able to adhere to the study
             visit schedule and other protocol requirements.

        Exclusion Criteria:

          1. Inadequate hepatic, nephritic and cardiac function:total bilirubin, ALT, AST,Cr more
             than two fold of upper normal level. cardiac function more than Grade II;

          2. Presence of Grade III nervous toxicity with two weeks;

          3. HBV virus load(HBV DNA)&gt; 1×10E5 copies/ml;

          4. Concomitant malignancy other than aggressive B cell lymphoma and need to treat;

          5. Concomitant with other hematologic diseases(such as leukemia,hemophilia primary
             myelofibrosis) which investigator it unsuitable to be enrolled into this clinical
             trial;

          6. Active and severe infectious diseases;

          7. Major surgery within three weeks;

          8. Any potential drug abuse, medical, psychological or social conditions which may
             disturb this investigation and assessment.

          9. In any conditions which investigator considered ineligible for this study. 10. Known
             sensitivity or allergy to investigational Product.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WEI XU, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Province Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LEI FAN, M.D., Ph.D.</last_name>
    <phone>86 25 6813 6034</phone>
    <email>fanlei_fl@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>ChangZhou First People's Hospital</name>
      <address>
        <city>ChangZhou</city>
        <state>Jiangsu</state>
        <zip>213003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XiangShan Cao, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>XiangShan Cao, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ChangZhou No.2 People's Hospital</name>
      <address>
        <city>ChangZhou</city>
        <state>Jiangsu</state>
        <zip>213011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Zhou, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Min Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HuaiAn First People's Hospital</name>
      <address>
        <city>HuaiAn</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Yu, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Liang Yu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JiangSu Province Hospital</name>
      <address>
        <city>NanJing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEI FAN, Dr.</last_name>
      <phone>86 25 6813 6034</phone>
    </contact>
    <investigator>
      <last_name>WEI XU, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NanJing First People's Hospital</name>
      <address>
        <city>NanJing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YanLi Xu, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>YanLi Xu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WuXi People's Hospital</name>
      <address>
        <city>WuXi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Zhuang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>YunFeng Shen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZhenJiang First People's Hospital</name>
      <address>
        <city>ZhenJiang</city>
        <state>Jiangsu</state>
        <zip>212002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Zhu, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Yan Zhu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>López A, Gutiérrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perelló A, Alarcón J, Martínez J, Rodríguez J. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 2008 Feb;80(2):127-32. Epub 2007 Nov 20.</citation>
    <PMID>18005385</PMID>
  </reference>
  <reference>
    <citation>Meriggi F, Zaniboni A. Gemox: a widely useful therapy against solid tumors-review and personal experience. J Chemother. 2010 Oct;22(5):298-303. Review.</citation>
    <PMID>21123151</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 19, 2012</lastchanged_date>
  <firstreceived_date>August 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jiangsu Province Hospital</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Rituximab</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>aggressive B cell lymphoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
